Hospital Admission of High Risk Infants for Respiratory Syncytial Virus Infection: Implications for Palivizumab Prophylaxis

Archives of Disease in Childhood: Fetal and Neonatal Edition - United Kingdom
doi 10.1136/adc.2003.029710
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

4cps-069 Evaluation of Palivizumab as Prophylaxis Against Respiratory Syncytial Virus Infection

2020English

The Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus-Associated Hospitalizations in Infants With Congenital Diaphragmatic Hernia

Pediatrics and Neonatology
Child HealthPediatricsPerinatology
2018English

Respiratory Syncytial Virus (RSV) Immune Globulin and Palivizumab for Prevention of RSV Infection

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2000English

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants

PharmacoEconomics - Open
Health PolicyPharmacology
2017English

Viral Load in Respiratory Syncytial Virus Infected Premature Newborns Under Prophylaxis With Palivizumab

Virology: Research and Reviews
2017English

Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection

Open Microbiology Journal
ImmunologyMicrobiology
2011English

Phosphatidylglycerol Provides Short-Term Prophylaxis Against Respiratory Syncytial Virus Infection

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2013English

Reliable Detection of Respiratory Syncytial Virus Infection in Children for Adequate Hospital Infection Control Management

Journal of Clinical Microbiology
Microbiology
2001English

Severe Respiratory Syncytial Virus Infection

Indian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy